Interview, Fireside Chat, Panel, Keynote
How Surbhi Sarna Built A $275M Biotech Company From Nothing
- The company's device is expected to provide definitive diagnosis for complex cysts, enabling rapid treatment initiation for cancerous cases while preventing unnecessary interventions for benign conditions.
- Strategic priorities involve accelerating product delivery to patients before pursuing an acquisition, with the expectation that a subsequent sale will secure the product's future and impact women's health.
- The speaker intends to leverage past operational struggles, failures, and mistakes to assist other founders in addressing their most difficult challenges and expediting time-to-market for technologies.
- Anticipated outcomes of this founder support include advancing innovations in agriculture and food safety, as well as developing improved medicines for cancer and early cancer detection capabilities.
- Selection criteria for YC applicants focus on founders who deeply understand their solutions and address genuine needs, without requiring exclusive reliance on MD or PhD credentials.